Lilly Expects FDA Action On Symbyax For Treatment-Resistant Depression In Second Half
This article was originally published in The Pink Sheet Daily
Executive Summary
After receiving an “approvable” letter in March for treatment-resistant depression, firm says it is working with the agency to determine labeling and post-marketing commitments.
You may also be interested in...
Grassley Seeking Zyprexa Lawsuit Documents
Senate Finance Committee ranking member requests all documents and materials relating to product liability litigation involving Lilly’s antipsychotic by April 25.
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.
MADIT-CRT Data Support Expanded Cardiac Resynchronization Market
The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.